Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination product** containing four bioactive compounds: - **Nicotinamide**: a form of vitamin B3, important in NAD+ biosynthesis, cellular energy metabolism, DNA repair, and anti-inflammatory effects. - **Palmitoylethanolamide (PEA)**: an endogenous fatty acid amide that acts as a peroxisome proliferator-activated receptor alpha (**PPARα**) agonist, known for analgesic, anti-inflammatory, and neuroprotective properties[5][1]. - **Oleoylethanolamide (OEA)**: an endogenous lipid that acts as a PPARα agonist and GPR119 agonist, with roles in appetite regulation, body weight control, anti-inflammatory, antioxidant, and neuroprotective activities[4][2][1]. - **Spermidine**: a polyamine involved in cellular growth and autophagy, with proposed roles in promoting cellular health, longevity, and neuroprotection. No unique combination drug or widely marketed pharmaceutical product containing just these four ingredients is identified in authoritative pharmaceutical registries as of the latest reports. The components are often individually researched as dietary supplements or investigational agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinamide + palmitoylethanolamide + oleoylethanolamide + spermidine.